Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-06

AUTHORS

Mark L. Wencel, Tmirah Haselkorn, Susan L. Limb, John L. Stauffer, Elizabeth Morgenthien, Karina Raimundo, Peter P. LaCamera

ABSTRACT

Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists. An online, self-administered survey was fielded to pulmonologists between April 10 and May 17, 2017. Pulmonologists were included if they spent > 20% of their time in direct patient care and had ≥ 5 patients with IPF on antifibrotic therapy. Participants answered questions regarding initiation of pirfenidone, dose titration, and management of potential AEs. A total of 169 pulmonologists participated. Gastrointestinal (GI) intolerance was the most important factor in implementing alternative titration schedules for pirfenidone. Approximately three-quarters of pulmonologists recommended the standard titration scheme for starting treatment; however, a range of titration schedules up to 8 weeks were described, with a 4-week schedule being most common. Pulmonologists reported that most patients treated with alternative titration schedules could achieve the full dose of pirfenidone. Pulmonologists who were most effective at mitigating pirfenidone-related GI AEs by advising dosing at mealtimes more frequently recommended taking pirfenidone during a substantial meal than pulmonologists who were less effective. For photosensitivity AEs, pulmonologists recommended sunscreen use, sun avoidance, wearing a hat, and ultraviolet protection factor clothing. Pulmonologists reported that alternative titration schedules for initiating pirfenidone were common and can aid in maintaining the full dose. Proposed strategies to ameliorate pirfenidone-related GI and photosensitivity AEs included taking pirfenidone during a substantial meal and minimizing sun exposure, respectively. F. Hoffmann-La Roche Ltd./Genentech, Inc. Plain language summary available for this article. More... »

PAGES

103-114

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41030-018-0056-8

DOI

http://dx.doi.org/10.1007/s41030-018-0056-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104292031


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Via Christi Health, Wichita, KS, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wencel", 
        "givenName": "Mark L.", 
        "id": "sg:person.01277475231.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277475231.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "EpiMetrix, Inc., Los Altos, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haselkorn", 
        "givenName": "Tmirah", 
        "id": "sg:person.01114603615.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114603615.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Limb", 
        "givenName": "Susan L.", 
        "id": "sg:person.01235104032.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235104032.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stauffer", 
        "givenName": "John L.", 
        "id": "sg:person.014532723522.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014532723522.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morgenthien", 
        "givenName": "Elizabeth", 
        "id": "sg:person.010443305144.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010443305144.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raimundo", 
        "givenName": "Karina", 
        "id": "sg:person.01320057745.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320057745.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St. Elizabeth's Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.240845.f", 
          "name": [
            "St. Elizabeth\u2019s Medical Center, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "LaCamera", 
        "givenName": "Peter P.", 
        "id": "sg:person.012627061353.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012627061353.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)60405-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009123817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.2009-040gl", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009587829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00026-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010604645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00026-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010604645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/13993003.00026-2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010604645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1402582", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013090473"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09059180.00011514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013692953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09059180.00011514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013692953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09059180.00011514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013692953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.201006-0894ci", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016956304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09059180.00001814", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023872794"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.38098", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028605529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lpm.2014.03.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028845877"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2213-2600(16)30326-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031351804"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.conctc.2016.04.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032404224"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.151322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050421346"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-014-0112-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051038083", 
          "https://doi.org/10.1007/s12325-014-0112-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmjresp-2015-000105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052683713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-017-0594-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091208529", 
          "https://doi.org/10.1007/s12325-017-0594-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-017-0594-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091208529", 
          "https://doi.org/10.1007/s12325-017-0594-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12890-017-0468-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091772986", 
          "https://doi.org/10.1186/s12890-017-0468-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12890-017-0468-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091772986", 
          "https://doi.org/10.1186/s12890-017-0468-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.chest.2017.08.468", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092326991"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/16000617.0057-2017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099614460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/16000617.0057-2017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099614460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/16000617.0057-2017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099614460"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-06", 
    "datePublishedReg": "2018-06-01", 
    "description": "Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists. An online, self-administered survey was fielded to pulmonologists between April 10 and May 17, 2017. Pulmonologists were included if they spent > 20% of their time in direct patient care and had \u2265 5 patients with IPF on antifibrotic therapy. Participants answered questions regarding initiation of pirfenidone, dose titration, and management of potential AEs. A total of 169 pulmonologists participated. Gastrointestinal (GI) intolerance was the most important factor in implementing alternative titration schedules for pirfenidone. Approximately three-quarters of pulmonologists recommended the standard titration scheme for starting treatment; however, a range of titration schedules up to 8 weeks were described, with a 4-week schedule being most common. Pulmonologists reported that most patients treated with alternative titration schedules could achieve the full dose of pirfenidone. Pulmonologists who were most effective at mitigating pirfenidone-related GI AEs by advising dosing at mealtimes more frequently recommended taking pirfenidone during a substantial meal than pulmonologists who were less effective. For photosensitivity AEs, pulmonologists recommended sunscreen use, sun avoidance, wearing a hat, and ultraviolet protection factor clothing. Pulmonologists reported that alternative titration schedules for initiating pirfenidone were common and can aid in maintaining the full dose. Proposed strategies to ameliorate pirfenidone-related GI and photosensitivity AEs included taking pirfenidone during a substantial meal and minimizing sun exposure, respectively. F. Hoffmann-La Roche Ltd./Genentech, Inc. Plain language summary available for this article.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s41030-018-0056-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1136859", 
        "issn": [
          "2364-1754", 
          "2364-1746"
        ], 
        "name": "Pulmonary Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis", 
    "pagination": "103-114", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "cf9c511cc6054b603a4ae8c34b19f9a8850fb5c9a98b3d1b63753731bd4768f4"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41030-018-0056-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104292031"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41030-018-0056-8", 
      "https://app.dimensions.ai/details/publication/pub.1104292031"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T01:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8697_00000565.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs41030-018-0056-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41030-018-0056-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41030-018-0056-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41030-018-0056-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41030-018-0056-8'


 

This table displays all metadata directly associated to this object as RDF triples.

167 TRIPLES      21 PREDICATES      45 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41030-018-0056-8 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N27fa43ffc68749c9a315732c58d12593
4 schema:citation sg:pub.10.1007/s12325-014-0112-1
5 sg:pub.10.1007/s12325-017-0594-8
6 sg:pub.10.1186/s12890-017-0468-5
7 https://doi.org/10.1002/art.38098
8 https://doi.org/10.1016/j.chest.2017.08.468
9 https://doi.org/10.1016/j.conctc.2016.04.008
10 https://doi.org/10.1016/j.lpm.2014.03.029
11 https://doi.org/10.1016/s0140-6736(11)60405-4
12 https://doi.org/10.1016/s2213-2600(16)30326-5
13 https://doi.org/10.1056/nejmoa1402582
14 https://doi.org/10.1136/bmjresp-2015-000105
15 https://doi.org/10.1164/rccm.2009-040gl
16 https://doi.org/10.1164/rccm.201006-0894ci
17 https://doi.org/10.1183/09059180.00001814
18 https://doi.org/10.1183/09059180.00011514
19 https://doi.org/10.1183/13993003.00026-2015
20 https://doi.org/10.1183/16000617.0057-2017
21 https://doi.org/10.3899/jrheum.151322
22 schema:datePublished 2018-06
23 schema:datePublishedReg 2018-06-01
24 schema:description Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists. An online, self-administered survey was fielded to pulmonologists between April 10 and May 17, 2017. Pulmonologists were included if they spent > 20% of their time in direct patient care and had ≥ 5 patients with IPF on antifibrotic therapy. Participants answered questions regarding initiation of pirfenidone, dose titration, and management of potential AEs. A total of 169 pulmonologists participated. Gastrointestinal (GI) intolerance was the most important factor in implementing alternative titration schedules for pirfenidone. Approximately three-quarters of pulmonologists recommended the standard titration scheme for starting treatment; however, a range of titration schedules up to 8 weeks were described, with a 4-week schedule being most common. Pulmonologists reported that most patients treated with alternative titration schedules could achieve the full dose of pirfenidone. Pulmonologists who were most effective at mitigating pirfenidone-related GI AEs by advising dosing at mealtimes more frequently recommended taking pirfenidone during a substantial meal than pulmonologists who were less effective. For photosensitivity AEs, pulmonologists recommended sunscreen use, sun avoidance, wearing a hat, and ultraviolet protection factor clothing. Pulmonologists reported that alternative titration schedules for initiating pirfenidone were common and can aid in maintaining the full dose. Proposed strategies to ameliorate pirfenidone-related GI and photosensitivity AEs included taking pirfenidone during a substantial meal and minimizing sun exposure, respectively. F. Hoffmann-La Roche Ltd./Genentech, Inc. Plain language summary available for this article.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N26eef801ec4a4e078748c482d23933c4
29 N289f6497d3074581983f6ad7ebe2a5e1
30 sg:journal.1136859
31 schema:name Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
32 schema:pagination 103-114
33 schema:productId N20696d47fd304d9084f5c9499ed960fb
34 N2c5f53d480554e28a9cc02270e0b9cfa
35 Nf40073299a124ee190d114a579fb9d6f
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104292031
37 https://doi.org/10.1007/s41030-018-0056-8
38 schema:sdDatePublished 2019-04-11T01:16
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher Nec4b91f91a714dc0a61e2a0f72cbef14
41 schema:url https://link.springer.com/10.1007%2Fs41030-018-0056-8
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N09d927c4c6e6491381ccddc32321199a schema:name Via Christi Health, Wichita, KS, USA
46 rdf:type schema:Organization
47 N0dba528552684c33a5fd301d0bb0e403 rdf:first sg:person.014532723522.53
48 rdf:rest N9db1247ce33e401e9c6836cf61e5ae29
49 N20696d47fd304d9084f5c9499ed960fb schema:name dimensions_id
50 schema:value pub.1104292031
51 rdf:type schema:PropertyValue
52 N26eef801ec4a4e078748c482d23933c4 schema:issueNumber 1
53 rdf:type schema:PublicationIssue
54 N27fa43ffc68749c9a315732c58d12593 rdf:first sg:person.01277475231.23
55 rdf:rest N86c950d7eccc42b3b1a45d609fb88b85
56 N289f6497d3074581983f6ad7ebe2a5e1 schema:volumeNumber 4
57 rdf:type schema:PublicationVolume
58 N29d05648086a484a86fcb5ade5a791f9 rdf:first sg:person.01320057745.28
59 rdf:rest N8b473e51cf824c60a30981f168a67220
60 N2c5f53d480554e28a9cc02270e0b9cfa schema:name readcube_id
61 schema:value cf9c511cc6054b603a4ae8c34b19f9a8850fb5c9a98b3d1b63753731bd4768f4
62 rdf:type schema:PropertyValue
63 N86c950d7eccc42b3b1a45d609fb88b85 rdf:first sg:person.01114603615.35
64 rdf:rest Ne88b5def3dad457cb77b48286680bb92
65 N8b473e51cf824c60a30981f168a67220 rdf:first sg:person.012627061353.07
66 rdf:rest rdf:nil
67 N9db1247ce33e401e9c6836cf61e5ae29 rdf:first sg:person.010443305144.57
68 rdf:rest N29d05648086a484a86fcb5ade5a791f9
69 Nd9b95803488a4340be472b60b174dd98 schema:name EpiMetrix, Inc., Los Altos, CA, USA
70 rdf:type schema:Organization
71 Ne88b5def3dad457cb77b48286680bb92 rdf:first sg:person.01235104032.61
72 rdf:rest N0dba528552684c33a5fd301d0bb0e403
73 Nec4b91f91a714dc0a61e2a0f72cbef14 schema:name Springer Nature - SN SciGraph project
74 rdf:type schema:Organization
75 Nf40073299a124ee190d114a579fb9d6f schema:name doi
76 schema:value 10.1007/s41030-018-0056-8
77 rdf:type schema:PropertyValue
78 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
79 schema:name Medical and Health Sciences
80 rdf:type schema:DefinedTerm
81 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
82 schema:name Public Health and Health Services
83 rdf:type schema:DefinedTerm
84 sg:journal.1136859 schema:issn 2364-1746
85 2364-1754
86 schema:name Pulmonary Therapy
87 rdf:type schema:Periodical
88 sg:person.010443305144.57 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
89 schema:familyName Morgenthien
90 schema:givenName Elizabeth
91 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010443305144.57
92 rdf:type schema:Person
93 sg:person.01114603615.35 schema:affiliation Nd9b95803488a4340be472b60b174dd98
94 schema:familyName Haselkorn
95 schema:givenName Tmirah
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114603615.35
97 rdf:type schema:Person
98 sg:person.01235104032.61 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
99 schema:familyName Limb
100 schema:givenName Susan L.
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235104032.61
102 rdf:type schema:Person
103 sg:person.012627061353.07 schema:affiliation https://www.grid.ac/institutes/grid.240845.f
104 schema:familyName LaCamera
105 schema:givenName Peter P.
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012627061353.07
107 rdf:type schema:Person
108 sg:person.01277475231.23 schema:affiliation N09d927c4c6e6491381ccddc32321199a
109 schema:familyName Wencel
110 schema:givenName Mark L.
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277475231.23
112 rdf:type schema:Person
113 sg:person.01320057745.28 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
114 schema:familyName Raimundo
115 schema:givenName Karina
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320057745.28
117 rdf:type schema:Person
118 sg:person.014532723522.53 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
119 schema:familyName Stauffer
120 schema:givenName John L.
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014532723522.53
122 rdf:type schema:Person
123 sg:pub.10.1007/s12325-014-0112-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051038083
124 https://doi.org/10.1007/s12325-014-0112-1
125 rdf:type schema:CreativeWork
126 sg:pub.10.1007/s12325-017-0594-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091208529
127 https://doi.org/10.1007/s12325-017-0594-8
128 rdf:type schema:CreativeWork
129 sg:pub.10.1186/s12890-017-0468-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091772986
130 https://doi.org/10.1186/s12890-017-0468-5
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1002/art.38098 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028605529
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1016/j.chest.2017.08.468 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092326991
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1016/j.conctc.2016.04.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032404224
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1016/j.lpm.2014.03.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028845877
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1016/s0140-6736(11)60405-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009123817
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1016/s2213-2600(16)30326-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031351804
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1056/nejmoa1402582 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013090473
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1136/bmjresp-2015-000105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052683713
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1164/rccm.2009-040gl schema:sameAs https://app.dimensions.ai/details/publication/pub.1009587829
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1164/rccm.201006-0894ci schema:sameAs https://app.dimensions.ai/details/publication/pub.1016956304
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1183/09059180.00001814 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023872794
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1183/09059180.00011514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013692953
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1183/13993003.00026-2015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010604645
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1183/16000617.0057-2017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099614460
159 rdf:type schema:CreativeWork
160 https://doi.org/10.3899/jrheum.151322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050421346
161 rdf:type schema:CreativeWork
162 https://www.grid.ac/institutes/grid.240845.f schema:alternateName St. Elizabeth's Medical Center
163 schema:name St. Elizabeth’s Medical Center, Boston, MA, USA
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.418158.1 schema:alternateName Roche (United States)
166 schema:name Genentech, Inc., South San Francisco, CA, USA
167 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...